Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:KMPHNASDAQ:MYOSNASDAQ:NRBONASDAQ:REXNNASDAQ:TOCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/ANRBONeuroBo Pharmaceuticals$3.10+1.3%$4.43$2.89▼$6.75$15.22M-0.251.04 million shs17,307 shsREXNRexahn Pharmaceuticals$2.06$1.26▼$4.26$8.11M0.98162,968 shs2,579 shsTOCATocagen$0.72-2.7%$32.24$0.42▼$6.77$17.13M0.011.47 million shs5,733 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%MYOSMYOS RENS Technology0.00%0.00%0.00%-50.36%+431.21%NRBONeuroBo Pharmaceuticals-1.29%-10.00%-28.84%-0.33%-43.91%REXNRexahn Pharmaceuticals0.00%0.00%0.00%0.00%0.00%TOCATocagen+2.65%-5.26%+4.08%-1.11%-29.62%Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/ANRBONeuroBo Pharmaceuticals1.1898 of 5 stars0.05.00.00.03.20.01.3REXNRexahn PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMPHZevra TherapeuticsN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AREXNRexahn PharmaceuticalsN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00MYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00NRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$3.44 per shareN/AREXNRexahn PharmaceuticalsN/AN/AN/AN/A$2.48 per shareN/ATOCATocagen$40K428.33N/AN/A$0.45 per share1.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/AMYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/ANRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-59.42%-45.40%5/10/2024 (Estimated)REXNRexahn Pharmaceuticals-$8.64MN/A0.00N/AN/AN/A-72.60%-55.68%N/ATOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKMPHZevra TherapeuticsN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AREXNRexahn PharmaceuticalsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMPHZevra Therapeutics0.1410.1010.10MYOSMYOS RENS Technology0.113.781.94NRBONeuroBo PharmaceuticalsN/A3.783.78REXNRexahn PharmaceuticalsN/A3.373.37TOCATocagen1.881.151.15OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMPHZevra Therapeutics19.39%MYOSMYOS RENS Technology4.97%NRBONeuroBo Pharmaceuticals1.37%REXNRexahn Pharmaceuticals7.49%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipKMPHZevra Therapeutics1.10%MYOSMYOS RENS Technology45.30%NRBONeuroBo Pharmaceuticals0.79%REXNRexahn Pharmaceuticals1.10%TOCATocagen10.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableNRBONeuroBo Pharmaceuticals24.91 million4.87 millionNot OptionableREXNRexahn Pharmaceuticals54.48 millionN/AOptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, MYOS, REXN, KMPH, and NRBO HeadlinesSourceHeadlineGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizpharmiweb.com - March 25 at 4:25 AMONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Gliomaascopubs.org - February 12 at 6:14 PMMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorseurekalert.org - January 20 at 12:14 AMForte Biosciences: Changes In Registrant S Certifying Accountantcbonds.com - December 12 at 8:27 AMRiskOn International And 3 Other Stocks Under $2 Insiders Are Buyingmarkets.businessinsider.com - December 11 at 9:20 AMPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedpharmaceutical-technology.com - November 6 at 9:33 AMProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board Appointmentfinance.yahoo.com - November 2 at 10:33 AMFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma Patientsprecisionmedicineonline.com - July 26 at 11:09 PMGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRnews.google.com - May 12 at 8:33 AMForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comnews.google.com - April 29 at 12:45 AMGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comnews.google.com - April 6 at 8:25 PMBelzutifan plus cabozantinib for patients with advanced clear cell ... - The Lancetnews.google.com - March 31 at 11:10 PMCurrent drug development and trial designs in neuro-oncology ... - The Lancetnews.google.com - March 28 at 12:07 AMCompanion Diagnostics Market is set to experience a significant ... - Digital Journalnews.google.com - March 27 at 8:37 AMOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital Journalnews.google.com - March 14 at 4:44 PMAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital Journalnews.google.com - March 8 at 10:39 AMAnaplastic Oligoastrocytoma Market Focus On Estimation, Research ... - Taiwan Newsnews.google.com - March 2 at 1:05 PMAnaplastic Oligoastrocytoma Market Industry Analysis, Estimates Size and Projections by 2029marketwatch.com - February 28 at 3:22 AMCompanion Diagnostics Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029marketwatch.com - February 27 at 9:31 AMAn echo through brain cancer’s empty pipelinepharmaphorum.com - February 7 at 7:04 PMCompanion Diagnostics Market Size, Share, Growth Statistics By ... - Digital Journalnews.google.com - February 3 at 6:12 AMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer - Yahoo Financenews.google.com - February 2 at 1:10 PMCardiff Oncology Announces the Appointment of Fairooz Kabbinavar ... - PR Newswirenews.google.com - February 2 at 8:09 AMHuman Resource Management Market Booming Worldwide With ... - Rejoice Magazinenews.google.com - January 27 at 11:36 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsZevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.NeuroBo PharmaceuticalsNASDAQ:NRBONeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Rexahn PharmaceuticalsNASDAQ:REXNOcuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.